Ocular surface disease in posttrabeculectomy/mitomycin C patients

Figures & data

Table 1 Etiology of glaucoma in eyes treated with trabeculectomy/MMC (n=15)

Etiology of glaucoma	% (n)
Primary
POAG	40.0 (6)
PACG	46.7 (7)
Secondary
Aphakic eye	6.7 (1)
Stevens–Johnson syndrome	6.7 (1)

Abbreviations: MMC, mitomycin C; POAG, primary open-angle glaucoma; PACG, primary angle-closure glaucoma.

Figure 1 Distribution of IOP-lowering eyedrops used to treat glaucoma.

Notes: Timolol maleate, a beta-adrenergic blocker, was the commonest IOP-lowering topical eyedrop used in these patients, followed by prostaglandin analogs and alpha-adrenergic blockers. In comparison, combination therapy and carbonic anhydrase inhibitors were used much less frequently in these patients.
Abbreviations: IOP, intraocular pressure; CA, carbonic anhydrase.

Table 2 Clinical findings of ocular surface disease

Clinical findings
Primary symptoms at presentation
Severe feeling of dryness	66.7%
Foreign body/gritty sensation	25.0%
Redness of eye	8.3%
Degree of dry eye disease
TBUT (seconds)	5.32±3.02
Schirmer I score (mm/5 min)	6.14±5.16

Abbreviation: TBUT, tear breakup time.

Figure 2 Corneal epitheliopathy in OSD.

Notes: Corneal epitheliopathy in these patients ranged from punctate epithelial erosions to epithelial defects, as seen in three different patients with eyes stained with fluorescein.
Abbreviation: OSD, ocular surface disease.

Table 3 Improvement in VA after treatment (using Snellen chart; N=15)

VA after treatment	n (%)
Improvement in VA	7 (46.7)
Gain ≥4 lines	2 (28.6)
Gain ≥2 lines and <4 lines	2 (28.6)
Gain 1 line	3 (42.9)
No improvement in VA	3 (20.0)
Worsening of VA	2 (13.3)
Lost to follow-up	(6.7)

Abbreviation: VA, visual acuity.